DNA Hypermethylation Suppresses Thyroid Peroxidase Expression and May Be a Promising Diagnostic Marker for Thyroid Cancer
Authors' conclusion
DNA hypermethylation suppresses TPO transcription by recruiting MBD2 in thyroid cancer. Quantitative assessment of TPO methylation by pyrosequencing offers a promising molecular diagnostic approach to distinguish malignant cancer from BTN. Further studies are warranted to ascertain the clinical diagnostic utility of these findings.
Study context
- Population
- Thyroid cancer (TCGA dataset, clinical tissue samples) and thyroid cancer cell lines MDA-T41, KTC-1, CAL62 and TTA1
- Comparison
- Malignant vs benign thyroid nodules
- Outcome
- Epigenetic basis of TPO silencing
Methodological detailsTCGA dataset analysis, validation in clinical tissue samples, cell line experiments
- TCGA dataset analysis
- Validation in clinical tissue samples
- Cell line experiments
Main finding
As reported in the abstract
- Thyroid peroxidase (TPO) expression markedly downregulated in thyroid cancer, strongly inversely correlated with methylation at TPO differentially methylated region (DMR)
- Decitabine significantly decreased TPO DMR methylation and increased TPO expression
- DNA hypermethylation suppressed TPO expression by recruiting MBD2
- Remarkable difference in TPO methylation (pyrosequencing) between malignant and BTN
Further findings
Diagnostic performance of two CpG sites within TPO DMR (malignant vs BTN)
- AUC, CpG site 1
- 0.927 (95% CI 0.864-0.989)
- AUC, CpG site 2
- 0.916 (95% CI 0.846-0.987)
Original publication
DNA Hypermethylation Suppresses Thyroid Peroxidase Expression and May Be a Promising Diagnostic Marker for Thyroid Cancer. Thyroid. Published 4 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →